{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:32:33Z","timestamp":1774614753816,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T00:00:00Z","timestamp":1533772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T00:00:00Z","timestamp":1533772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s10620-018-5235-9","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T09:58:33Z","timestamp":1533808713000},"page":"158-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial)"],"prefix":"10.1007","volume":"64","clinical-trial-number":[{"clinical-trial-number":"nct02623816","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Abhijeet","family":"Waghray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisheet","family":"Waghray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam T.","family":"Perzynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Votruba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Michael","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,9]]},"reference":[{"key":"5235_CR1","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/S0016-5085(97)70025-8","volume":"112","author":"GR Locke 3rd","year":"1997","unstructured":"Locke GR 3rd, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448\u20131456.","journal-title":"Gastroenterology"},{"key":"5235_CR2","first-page":"191","volume":"17","author":"SB Jenkins","year":"2001","unstructured":"Jenkins SB, Leng BL, Shortland JR, et al. Sclerosing encapsulating peritonitis: a case series from a single U.K. center during a 10-year period. Adv Perit Dial Conf Perit Dial. 2001;17:191\u2013195.","journal-title":"Adv Perit Dial Conf Perit Dial"},{"key":"5235_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1365-2036.2007.03366.x","volume":"26","author":"HK Jung","year":"2007","unstructured":"Jung HK, Halder S, McNally M, et al. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Therap. 2007;26:453\u2013461.","journal-title":"Aliment Pharmacol Therap"},{"key":"5235_CR4","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/0016-5085(92)90764-P","volume":"102","author":"NJ Talley","year":"1992","unstructured":"Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology. 1992;102:1259\u20131268.","journal-title":"Gastroenterology"},{"key":"5235_CR5","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1053\/j.gastro.2004.03.077","volume":"126","author":"HB El-Serag","year":"2004","unstructured":"El-Serag HB, Petersen NJ, Carter J, et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology. 2004;126:1692\u20131699.","journal-title":"Gastroenterology"},{"key":"5235_CR6","volume-title":"The Burden of Gastrointestinal Diseases","author":"AG Association","year":"2001","unstructured":"Association AG. The Burden of Gastrointestinal Diseases, vol. 2006. Bethesda, MD: AGA; 2001."},{"key":"5235_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1365-2036.2006.02996.x","volume":"24","author":"P Wahlqvist","year":"2006","unstructured":"Wahlqvist P, Reilly MC, Barkun A. Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Therap. 2006;24:259\u2013272.","journal-title":"Aliment Pharmacol Therap"},{"key":"5235_CR8","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1053\/j.gastro.2008.12.015","volume":"136","author":"JE Everhart","year":"2009","unstructured":"Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009;136:376\u2013386.","journal-title":"Gastroenterology"},{"key":"5235_CR9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1046\/j.1365-2036.1997.00185.x","volume":"11","author":"JP Galmiche","year":"1997","unstructured":"Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Therap. 1997;11:765\u2013773.","journal-title":"Aliment Pharmacol Therap"},{"key":"5235_CR10","first-page":"96","volume":"30","author":"M Guslandi","year":"1983","unstructured":"Guslandi M, Testoni PA, Passaretti S, et al. Ranitidine vs metoclopramide in the medical treatment of reflux esophagitis. Hepato-gastroenterology. 1983;30:96\u201398.","journal-title":"Hepato-gastroenterology"},{"key":"5235_CR11","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.1021\/bi047761p","volume":"44","author":"K Munson","year":"2005","unstructured":"Munson K, Garcia R, Sachs G. Inhibitor and ion binding sites on the gastric H, K-ATPase. Biochemistry. 2005;44:5267\u20135284.","journal-title":"Biochemistry"},{"key":"5235_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/290159a0","volume":"290","author":"E Fellenius","year":"1981","unstructured":"Fellenius E, Berglindh T, Sachs G, et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H\u2009+\u2009+\u2009K\u2009+)ATPase. Nature. 1981;290:159\u2013161.","journal-title":"Nature"},{"key":"5235_CR13","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1053\/gast.2002.32978","volume":"122","author":"RS Sandler","year":"2002","unstructured":"Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500\u20131511.","journal-title":"Gastroenterology"},{"key":"5235_CR14","unstructured":"2012 IIfHITuomitUSroA. www.imshealth.com\/ims\/Global\/Content\/Insights\/IMS%20Institute%20for%20Healthcare%20Informatics\/IHII_Medicines_in_U.S_Report_2011.pdf. Accessed January 15, 2017."},{"key":"5235_CR15","doi-asserted-by":"crossref","first-page":"7690","DOI":"10.1016\/S0021-9258(17)32907-1","volume":"251","author":"G Sachs","year":"1976","unstructured":"Sachs G, Chang HH, Rabon E, et al. A nonelectrogenic H\u2009+\u2009pump in plasma membranes of hog stomach. J Biol Chem. 1976;251:7690\u20137698.","journal-title":"J Biol Chem"},{"key":"5235_CR16","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","volume":"112","author":"N Chiba","year":"1997","unstructured":"Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798\u20131810.","journal-title":"Gastroenterology"},{"key":"5235_CR17","first-page":"003245","volume":"2","author":"C Donnellan","year":"2010","unstructured":"Donnellan C, Preston C, Moayyedi P, et al. WITHDRAWN: medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2010;2:003245.","journal-title":"Cochrane Database Syst Rev"},{"key":"5235_CR18","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/S0016-5085(00)70004-7","volume":"118","author":"MM Wolfe","year":"2000","unstructured":"Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;118:S9\u2013S31.","journal-title":"Gastroenterology"},{"key":"5235_CR19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/ajg.2013.421","volume":"109","author":"I Sheikh","year":"2014","unstructured":"Sheikh I, Waghray A, Waghray N, et al. Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease. The American Journal of Gastroenterology. 2014;109:789\u2013794.","journal-title":"The American journal of gastroenterology."},{"key":"5235_CR20","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2165\/11595480-000000000-00000","volume":"31","author":"S Toghanian","year":"2011","unstructured":"Toghanian S, Johnson DA, Stalhammar NO, et al. Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: a post hoc analysis of the 2007 national health and wellness survey. Clin Drug Invest. 2011;31:703\u2013715.","journal-title":"Clin Drug Invest"},{"key":"5235_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1572-0241.2003.07186.x","volume":"98","author":"BC Jacobson","year":"2003","unstructured":"Jacobson BC, Ferris TG, Shea TL, et al. Who is using chronic acid suppression therapy and why? Am J Gastroenterol. 2003;98:51\u201358.","journal-title":"Am J Gastroenterol"},{"key":"5235_CR22","volume-title":"Drug Class Review: Proton Pump Inhibitors","author":"MS McDonagh","year":"2009","unstructured":"McDonagh MS, Carson S, Thakurta S. Drug Class Review: Proton Pump Inhibitors, vol. 5. Portland, OR: Final Report Update; 2009."},{"key":"5235_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00003088-199937050-00003","volume":"37","author":"KA Rodvold","year":"1999","unstructured":"Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet. 1999;37:385\u2013398.","journal-title":"Clin Pharmacokinet"},{"key":"5235_CR24","volume-title":"Acid Related Disorders Mystery to Mechanism: Mechanism to Management","author":"GPC Sachs","year":"1995","unstructured":"Sachs GPC, Hersey S. Acid Related Disorders Mystery to Mechanism: Mechanism to Management. Dominguez: SUSHU Communications Inc.; 1995."},{"key":"5235_CR25","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1136\/gut.25.9.957","volume":"25","author":"BK Sharma","year":"1984","unstructured":"Sharma BK, Walt RP, Pounder RE, et al. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut. 1984;25:957\u2013964.","journal-title":"Gut"},{"key":"5235_CR26","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJM199510263331703","volume":"333","author":"S Vigneri","year":"1995","unstructured":"Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333:1106\u20131110.","journal-title":"N Engl J Med"},{"key":"5235_CR27","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/ajg.2013.69","volume":"108","author":"DO Francis","year":"2013","unstructured":"Francis DO, Rymer JA, Slaughter JC, et al. High economic burden of caring for patients with suspected extraesophageal reflux. Am J Gastroenterol. 2013;108:905\u2013911.","journal-title":"Am J Gastroenterol"},{"key":"5235_CR28","first-page":"463","volume":"49","author":"AP Hungin","year":"1999","unstructured":"Hungin AP, Rubin G, O\u2019Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gener Pract. 1999;49:463\u2013464.","journal-title":"Br J Gener Pract"},{"key":"5235_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","volume":"22","author":"R Fass","year":"2005","unstructured":"Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease\u2013where next? Aliment Pharmacol Therap. 2005;22:79\u201394.","journal-title":"Aliment Pharmacol Therap"},{"key":"5235_CR30","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","volume":"73","author":"W Gomm","year":"2016","unstructured":"Gomm W, von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410\u2013416.","journal-title":"JAMA Neurol"},{"key":"5235_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176:238\u2013246.","journal-title":"JAMA Intern Med"},{"key":"5235_CR32","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/MOG.0b013e328358d5b9","volume":"28","author":"NS Abraham","year":"2012","unstructured":"Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol. 2012;28:615\u2013620.","journal-title":"Curr Opin Gastroenterol"},{"key":"5235_CR33","doi-asserted-by":"publisher","first-page":"800-8e7","DOI":"10.1016\/j.cgh.2017.09.033","volume":"16","author":"DY Graham","year":"2018","unstructured":"Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018;16:800-8e7.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5235_CR34","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/j.1572-0241.2006.00998.x","volume":"102","author":"DC Metz","year":"2007","unstructured":"Metz DC, Inadomi JM, Howden CW, et al. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol. 2007;102:642\u2013653.","journal-title":"Am J Gastroenterol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-018-5235-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5235-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5235-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:09:10Z","timestamp":1628597350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-018-5235-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,9]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["5235"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5235-9","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733797369.793549508","asserted-by":"object"}]},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,9]]},"assertion":[{"value":"18 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no financial or grant support or conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}